2.24

3.03% -0.07

After Hours: 2.24

Aclaris Therapeutics Inc (ACRS)

Overview News Price History Option Chain Financials Why ACRS Down? Discussions Forecast

Aclaris Therapeutics Inc stock is traded at $2.24, with a volume of 369.00K. It is down -3.03% in the last 24 hours and down -13.85% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Previous Close:

$2.31

Open:

$2.29

24h Volume:

369.00K

Relative Volume:

0.16

Market Cap:

$239.72M

Revenue:

$27.08M

Net Income/Loss:

$-37.00M

P/E Ratio:

-4.3077

EPS:

-0.52

Net Cash Flow:

$-18.46M

1W Performance:

-3.86%

1M Performance:

-13.85%

6M Performance:

+76.38%

1Y Performance:

+86.67%

1-Day Range:

$2.22

$2.335

1-Week Range:

$2.22

$2.415

52-Week Range:

$0.9515

$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name

Aclaris Therapeutics Inc

Sector

Healthcare (1169)

Industry

Diagnostics & Research (60)

Phone

484-324-7933

Address

701 LEE ROAD, WAYNE, PA

Employee

Twitter

@aclaristx

Next Earnings Date

2025-02-21

Latest SEC Filings

ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRS Aclaris Therapeutics Inc	2.24	239.72M	27.08M	-37.00M	-18.46M	-0.52
TMO Thermo Fisher Scientific Inc	532.55	203.70B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	210.23	151.18B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	135.37	38.62B	6.51B	1.29B	1.37B	4.42
IDXX Idexx Laboratories Inc	452.77	37.07B	3.90B	887.87M	808.08M	10.67
IQV Iqvia Holdings Inc	191.04	33.64B	15.41B	1.37B	2.11B	7.50

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy
Nov-19-24	Upgrade	Jefferies	Hold → Buy
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-01-22	Initiated	Goldman	Buy
Oct-06-22	Initiated	BTIG Research	Buy
Jul-23-21	Resumed	Jefferies	Buy
Jun-15-21	Initiated	Piper Sandler	Overweight
Apr-21-21	Initiated	H.C. Wainwright	Buy
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform
Mar-28-18	Resumed	Leerink Partners	Outperform
Feb-09-18	Initiated	Guggenheim	Buy
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
Nov-29-16	Initiated	Leerink Partners	Outperform
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy
Nov-02-15	Initiated	Citigroup	Buy
Nov-02-15	Initiated	Jefferies	Buy

View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

Feb 20, 2025

Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday - MarketBeat

Feb 20, 2025

Common Warts Market to Expand Significantly by 2034, States - openPR

Feb 20, 2025

Feb 18, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in January - MarketBeat

Feb 18, 2025

Peapod Lane Capital LLC Takes $1 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat

Feb 18, 2025

Feb 17, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World

Feb 17, 2025

Feb 14, 2025

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN

Feb 14, 2025

Feb 12, 2025

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewswire

Feb 12, 2025

Clinical Data: Revolutionary Dual-Target Drug Shows Promise for Multiple Autoimmune Conditions - StockTitan

Feb 12, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Feb 12, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Feb 12, 2025

Feb 11, 2025

Financial Metrics Check: Aclaris Therapeutics Inc (ACRS)’s Ratios for Trailing Twelve Months - The Dwinnex

Feb 11, 2025

Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha

Feb 11, 2025

Feb 10, 2025

What is Leerink Partnrs' Forecast for ACRS FY2029 Earnings? - MarketBeat

Feb 10, 2025

H.C. Wainwright gives a Buy recommendation for Aclaris Therapeutics Inc (ACRS) - Knox Daily

Feb 10, 2025

Leerink Partnrs Has Negative Outlook of ACRS FY2025 Earnings - MarketBeat

Feb 10, 2025

Feb 08, 2025

Research Analysts Issue Forecasts for ACRS FY2029 Earnings - Armenian Reporter

Feb 08, 2025

StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World

Feb 08, 2025

Feb 07, 2025